Immunome Inc. Cash Flow Statement
IMNM / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Immunome Inc. used $191M in operating cash flow and negative free cash flow of $201M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 4.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$212.4M | -$293.0M | -$36.9M | -$36.9M | -$24.7M | -$17.8M | -$10.4M |
| Depreciation & Amortization | $2.5M | $1.6M | $422.0K | $422.0K | $755.0K | $755.0K | $615.0K |
| Operating Cash Flow | -$190.9M | -$110.8M | -$28.7M | -$28.7M | -$18.2M | -$12.1M | -$9.6M |
| Capital Expenditures | $9.7M | $7.2M | $248.0K | $248.0K | $79.0K | $586.0K | $233.0K |
| Free Cash Flow | -$200.6M | -$118.0M | -$28.9M | -$28.9M | -$18.3M | -$12.7M | -$9.8M |
| FCF Margin | -2890.1% | -1304.8% | -206.4% | - | - | - | - |